PCR

Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens

Retrieved on: 
Friday, March 8, 2024
Research, Genetics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Gene expression profiling, Breast cancer, Neoplasm, Taxane, Woman, Transcriptome, MD, MBCC, Cyclophosphamide, Anthracycline, PCR, MammaPrint, Risk, Conference, Symantec Endpoint Protection, AC-T, Patient, MP, Diagnosis, Triple-negative breast cancer, Blueprint, TC, Medical imaging

The first poster, titled MammaPrint® and BluePrint® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.

Key Points: 
  • The first poster, titled MammaPrint® and BluePrint® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.
  • ), investigates the associations between MammaPrint and BluePrint classifications, therapy regimen, and the likelihood of achieving a pathologic Complete Response (pCR).
  • The second poster, titled Prediction of chemotherapy benefit by MammaPrint® in patients with HR+HER2-early-stage breast cancer from real-world evidence studies (Audeh, W., et al.
  • Taken together, these findings indicate the utility of MammaPrint to predict neoadjuvant and adjuvant chemotherapy benefit in this patient population.

CleanNA launches CE-IVD product for quick and reliable viral DNA and RNA extraction

Retrieved on: 
Wednesday, March 6, 2024
Health, Medical Devices, Genetics, Research, Science, Pharmaceutical, Biotechnology, Bureau Veritas, DNA, COVID 19, RNA, RUO, PCR, COVID, Vaccine

The company’s Clean Quick Viral DNA/RNA (CE-IVD) extracts viral DNA and RNA from nasopharyngeal or oropharyngeal swab samples preserved in an inactivating viral transport medium.

Key Points: 
  • The company’s Clean Quick Viral DNA/RNA (CE-IVD) extracts viral DNA and RNA from nasopharyngeal or oropharyngeal swab samples preserved in an inactivating viral transport medium.
  • Clean Quick Viral DNA/RNA is based on magnetic beads, which makes the protocol easy to automate on CleanNA’s CleanXtract 96 or general liquid handlers.
  • CleanNA developed the Clean Quick Viral DNA/RNA for use in diagnostic workflows, that is why the product is CE-IVD marked.
  • “Clean Quick Viral DNA/RNA is the next CE-IVD marked product we launch in a short period of time.

Revolutionary Elephant iPSC Milestone Reached in Colossal’s Woolly Mammoth Project

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Technology, Health, Environmental Issues, Environmental Health, Other Science, Research, Software, Genetics, Environment, Science, Hoechst, KLF4, CRISPR, Woolly mammoth, Multimedia, Cattle, Growth, Harvard University, Cell, Developmental biology, TP53, Gametogenesis, Colossal Biosciences, Factorization of polynomials, Life, Elephant, IPSC, MYC, Cat, Genome, Gene, OCT4, Rhinoceros, Publication, PCR, Biology, Cancer, Hunting

Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced pluripotent stem cells) breakthrough.

Key Points: 
  • Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced pluripotent stem cells) breakthrough.
  • This milestone advancement was one of the primary early goals of the mammoth project, and supports the feasibility of future multiplex ex utero mammoth gestation.
  • Invaluable for Colossal’s Woolly Mammoths, these cells can be multiplex-edited and differentiated to study cold adaptation traits like woolly hair growth and fat storage in cellular and organoid models.
  • “In the past, a multitude of attempts to generate elephant iPSCs have not been fruitful.

Elevate Your Morning Ritual with Elmhurst 1925's Multi-Serve Lattes - Where Clean Ingredients and Rich Coffee Flavors Unite!

Retrieved on: 
Wednesday, February 28, 2024
Women, Fitness & Nutrition, Supermarket, Men, Family, Food, Beverage, Health, Consumer, Retail, Sprouts, Love, Kroger, Thrive Market, Erewhon, Multimedia, Steam, Carrageenan, Caffeine, Grain, ALA, The Fresh Market, Dietary fiber, Plant, Grain boundary strengthening, Ice, Orthodox Union Kosher, Milk, Tree, Coffee, Hydroelectricity, Amazon (company), Oil, Amazon, Bristol Farms, Recycling, SRP, PCR, FSC, Sprout, Vanilla, Water

Like all Elmhurst products, they contain minimal ingredients and are free from gums, oils and added fillers.

Key Points: 
  • Like all Elmhurst products, they contain minimal ingredients and are free from gums, oils and added fillers.
  • Plus, each 24 oz carton contains (2) 12 oz servings, so consumers can enjoy multiple lattes or share with a friend.
  • "This commitment to continuous innovation has led us to craft the ultimate dairy-free lattes for coffee lovers.
  • Unlike other plant-based lattes made with unnecessary preservatives, artificial flavors, carrageenan, gums, fillers, oils and emulsifiers, Elmhurst’s are crafted with only the simplest ingredients.

Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup

Retrieved on: 
Wednesday, February 28, 2024
Medical Devices, Health, Other Science, Research, Science, Biotechnology, Acquisition, Hospital, Infection, Cystic fibrosis, Microbiology, MALDI, Mycobacterium, MDX, Fungal infection, PAI Partners, PAI, COVID, BRKR, Tuberculosis, Hand, Corporation, PCR, HIV, IVD, Partnership

This put option has now been exercised, and the parties have entered into a binding share purchase agreement.

Key Points: 
  • This put option has now been exercised, and the parties have entered into a binding share purchase agreement.
  • ELITechGroup, with over 500 employees and over 40 active patents, develops and commercializes innovative, proprietary molecular diagnostic (MDx) systems and assays, as well as niche biomedical systems and microbiology products.
  • Establishing this unique business within Bruker - a well-respected global life-science tools and specialty diagnostics company - provides an exciting opportunity to further grow our molecular diagnostics, microbiology and biomedical systems portfolios.
  • Upon closing, ELITech is expected to be a stand-alone business within Bruker’s Microbiology and Infection Diagnostics division, as a part of the Bruker CALID Group.

Syndromic Multiplex Diagnostic Markets with COVID-19 Impacts, Strategies and Trends, Forecasts and Executive Guides & Customization - Global Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 26, 2024
Other Health, Health, Science, Pharmaceutical, Research, POCT, DTC, RSV, Live, SARS-CoV-2, PCR, STI, Disease

5.2.3 Infectious Disease is Declining But..

Key Points: 
  • 5.2.3 Infectious Disease is Declining But..
    5.2.5 Economic Growth improves Living Standards.
  • 5.3.3 Syndrome Testing Moving to Big Instruments?
  • 5.4.6 Syndromics drives POCT adoption.
  • 5.4.7 A Big Future for PCR?

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test

Retrieved on: 
Thursday, March 7, 2024
Influenza, Hepatitis B, CDSCO, FDA, Point-of-care testing, Growth, 2005 in television, Sale, ABC, Euro starter kits, Malaria, COVID-19, Fever Dream, RT, Mycobacterium tuberculosis, HPV, Chikungunya, PCR, Hepatitis C, IVD, Vaccine

SALT LAKE CITY, March 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAPLEX™ Influenza Multiplex (IFM) Test Kit to clinical laboratories as an in vitro diagnostic ("IVD") for the detection and differentiation of Influenza A and Influenza B.

Key Points: 
  • Co-Primers utilize a unique design architecture to combat common issues with real-time PCR that can lead to inaccurate results, specifically primer dimer propagation, and which are magnified in multiplex reactions.
  • "The importance of accurate, reliable PCR testing at the high-throughput clinical laboratory level remains critical," remarked Dwight Egan, CEO of Co-Diagnostics.
  • *The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
  • The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.

The HC Companies Introduces 10% PCR Content in Horticultural Containers

Retrieved on: 
Wednesday, March 6, 2024
HC, Plastic, Biophysical environment, BioPAX, PCR, Certification, Organization, Environment

The HC Companies continues to set the industry standard for sustainability by incorporating an average of 50% recycled content with a minimum of 10% PCR (Post-Consumer Recycled) content across all their horticultural containers.

Key Points: 
  • The HC Companies continues to set the industry standard for sustainability by incorporating an average of 50% recycled content with a minimum of 10% PCR (Post-Consumer Recycled) content across all their horticultural containers.
  • This initiative not only will integrate at least 10% PCR content across the majority of their product lines, but will also receive credible third-party certification to guarantee transparency in our supply chains.
  • The HC Companies offers more than just products; they serve as partners in ESG (Environmental, Social, and Governance) data and reporting support for horticultural containers.
  • By collaborating with The HC Companies, organizations can not only meet regulatory requirements but also strengthen their commitment to sustainability.

Hybribio Calls for Raising International HPV Awareness

Retrieved on: 
Monday, March 4, 2024
International, Hospital, Cervical cancer, Woman, IPVS, SOX1, Methylation, Cancer, Human papillomavirus infection, Wart, Vaccination, World Health Organization, Fluorescence, Organization, HPV, Vagina, WHO, PCR, NMPA

On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.

Key Points: 
  • On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.
  • In this case, raising HPV awareness, getting timely vaccination and high-quality screening together contribute significantly to the prevention of HPV infection and related diseases.
  • Hybribio has developed a complete HPV molecular diagnostic solution covering 14 High-risk HPV GenoArray Diagnostic Kit, 14 High-risk HPV with 16/18 Genotyping Real-time PCR Kit, 14 High-risk HPV E6/E7 mRNA Real-time PCR Kit (PCR with Fluorescent Probe), 21 HPV GenoArray Diagnostic Kit, 37 HPV GenoArray Diagnostic Kit, 13 High-risk HPV Real-time PCR Kit, 23 HPV Genotyping Real-time PCR Kit, SOX1 and PAX1 Methylation Real-time PCR Kit.
  • Raising international HPV awareness is the very first step against cervical cancer.

Hybribio Calls for Raising International HPV Awareness

Retrieved on: 
Monday, March 4, 2024
International, Hospital, Cervical cancer, Woman, IPVS, SOX1, Methylation, Cancer, Human papillomavirus infection, Wart, Vaccination, World Health Organization, Fluorescence, Organization, HPV, Vagina, WHO, PCR, NMPA

On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.

Key Points: 
  • On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.
  • In this case, raising HPV awareness, getting timely vaccination and high-quality screening together contribute significantly to the prevention of HPV infection and related diseases.
  • Hybribio has developed a complete HPV molecular diagnostic solution covering 14 High-risk HPV GenoArray Diagnostic Kit, 14 High-risk HPV with 16/18 Genotyping Real-time PCR Kit, 14 High-risk HPV E6/E7 mRNA Real-time PCR Kit (PCR with Fluorescent Probe), 21 HPV GenoArray Diagnostic Kit, 37 HPV GenoArray Diagnostic Kit, 13 High-risk HPV Real-time PCR Kit, 23 HPV Genotyping Real-time PCR Kit, SOX1 and PAX1 Methylation Real-time PCR Kit.
  • Raising international HPV awareness is the very first step against cervical cancer.